IMPROVED DELIVERY OF ANTIVIRALS FOR CNS INFECTIONS

Award Information

Agency: Department of Health and Human Services	Branch: N/A	Award ID: 8098	Program Year/Program: 1988 / SBIR
Agency Tracking Number: 8098	Solicitation Year: N/A	Solicitation Topic Code: N/A	Solicitation Number: N/A

Small Business Information: Pharmos Corporation
2 INNOVATION DR Alachua, FL 32615
View profile »

Woman-Owned: No

Minority-Owned: No

HUBZone-Owned: No

Phase 1: Fiscal Year: 1988

Title: IMPROVED DELIVERY OF ANTIVIRALS FOR CNS INFECTIONS

Agency: HHS

Contract: N/A

Award Amount: $50,000.00

Abstract:
HUMAN CYTOMEGALOVIRUS (HCMV) IS A COMMON AND NOT USUALLY SERIOUS INFECTIVE AGENT. HOWEVER, IN THE CASE OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) AND OTHER IMMUNO-SUPPRESSEDSTATES, HCMV IS INORDINATELY VIRULENT AND IS EVEN A MAJOR CAUSE OF DEATH. RECENTLY, TREATMENT OF HCMV INFECTIONS IN IMMUNOSUPPRESSED STATES HAS BEEN DRAMATICALLY IMPROVED THROUGH THE INTRODUCTION OF A NEW ANTIVIRAL COMPOUND, 9-(1,3-DIHYDROXY)-2-PROPOXYMETHYL)GUANINE, DHPG, WHICH IS ALSO KNOWN AS GANCICLOVIR. HCMV INFECTIONS OF THE CENTRAL NERVOUS SYSTEM (CNS) ARE, HOWEVER, RESISTANT TO ANTIVIRAL THERAPY, DUE MAINLY TO THE PRESENCE OF THE BLOOD-BRAIN BARRIER (BBB), WHICH EFFECTIVELYPREVENTS ACCESS TO THE CNS OF HYDROPHILIC COMPOUNDS SUCH AS DHPG. WE PROPOSE TO INVESTIGATE THE APPLICATION OF A CHEMICAL DELIVERY SYSTEM (CDS) FOR DELIVERY OF DHPG TO THE CNS. THIS WORK WOULD INVOLVE SYNTHESIS OF SEVERAL COMPOUNDS, INVESTIGATION OF THEIR PHYSICAL AND CHEMICAL PROPERTIES, AND INITIAL STUDY OF THEIR DISTRIBUTIONAL PROFILES IN ANIMAL MODELS.

Principal Investigator:

0

Business Contact:

Small Business Information at Submission:

Pharmatec Inc
Box 730 Alachua, FL 32615

EIN/Tax ID:

DUNS: N/A

Number of Employees: N/A

Woman-Owned: No

Minority-Owned: No

HUBZone-Owned: No